InterVenn

San Francisco, United States Founded: 2017 • Age: 9 yrs
Provider of an AI-based clinical decision supporting tool for cancer detection and drug development
Request Access

About InterVenn

InterVenn is a company based in San Francisco (United States) founded in 2017.. InterVenn has raised $250.9 million across 6 funding rounds from investors including SoftBank Group, Genoa Ventures and Heritage Provider Network. InterVenn offers products and services including GlycoVision and Liquid Biopsy Platform. InterVenn operates in a competitive market with competitors including Miroculus, Geneoscopy, HalioDx, Magentiq Eye and AcuamarkDx, among others.

  • Headquarter San Francisco, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $250.9 M (USD)

    in 6 rounds

  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of InterVenn

InterVenn offers a comprehensive portfolio of products and services, including GlycoVision and Liquid Biopsy Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for analyzing glycoprotein structures in precision medicine.

Tool for detecting diseases through glycoproteome insights.

People of InterVenn
Headcount 50-200
Employee Profiles 12
Board Members and Advisors 15
Employee Profiles
People
Charmie Raterta
Senior Accounting Manager
People
Jeremy Franzen
Vice President Technology Operations / CISO
People
Ada Wong
VP, Intellectual Property
People
Marie Ann Paraiso-Recidoro
Senior Business Analyst

Unlock access to complete

Board Members and Advisors
people
Padmanee Sharma
Advisor
people
James Allison
Advisor
people
Regina Benjamin
Advisor
people
Arnold Levine
Advisor

Unlock access to complete

Funding Insights of InterVenn

InterVenn has successfully raised a total of $250.9M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round
  • First Round

    (03 Oct 2018)

  • Investors Count 11
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2022 Amount Series C - InterVenn Valuation Genoa Ventures
Aug, 2021 Amount Series C - InterVenn Valuation SoftBank Group , Heritage Provider Network
Nov, 2020 Amount Series B - InterVenn Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in InterVenn

InterVenn has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include SoftBank Group, Genoa Ventures and Heritage Provider Network. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage VC firm focused on life science startups
Founded Year Domain Location
Early-stage startups are invested in by sector-agnostic VC fund.
Founded Year Domain Location
Technical founders are supported through early-stage venture capital investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by InterVenn

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - InterVenn

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Intervenn Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of InterVenn

InterVenn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Miroculus, Geneoscopy, HalioDx, Magentiq Eye and AcuamarkDx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
MicroRNA profiling platform is developed to detect genes in samples.
domain founded_year HQ Location
Non-invasive biomarker tests for colorectal cancer are developed.
domain founded_year HQ Location
Developer of diagnostic product for colon cancer
domain founded_year HQ Location
Computer vision software is utilized for endoscopic medical procedures.
domain founded_year HQ Location
Non-invasive screening tests for early cancer detection are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about InterVenn

When was InterVenn founded?

InterVenn was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is InterVenn located?

InterVenn is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Who is the current CEO of InterVenn?

Andrew Quong is the current CEO of InterVenn.

Is InterVenn a funded company?

InterVenn is a funded company, having raised a total of $250.9M across 6 funding rounds to date. The company's 1st funding round was a Series B of $34M, raised on Oct 03, 2018.

What does InterVenn do?

Provider of an AI-based clinical decision supporting tool for cancer detection and drug development. The company has developed tools like Dawn which is immune-oncology testing software that uses glycoproteomics and AI. The VISTA tool assists with the quantification of proteins in serum or blood. It has features to analyze clinical biomarkers for disease diagnosis, drug development, and treatment prediction. The VOCAL is a diagnostic tool for detecting cancer in ovaries.

Who are the top competitors of InterVenn?

InterVenn's top competitors include Geneoscopy, AcuamarkDx and Miroculus.

What products or services does InterVenn offer?

InterVenn offers GlycoVision and Liquid Biopsy Platform.

Who are InterVenn's investors?

InterVenn has 11 investors. Key investors include SoftBank Group, Genoa Ventures, Heritage Provider Network, Irving Investors, and Amplify Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available